Advances in the application of aberrant DNA methylation in the diagnosis and treatment of lung cancer.
10.3760/cma.j.cn112150-20220825-00841
- Author:
Yu YANG
1
;
Yan Li CHEN
1
;
Xiao Tao ZHAO
1
Author Information
1. Department of Laboratory Medicine, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Humans;
DNA Methylation;
Lung Neoplasms/therapy*;
Lung
- From:
Chinese Journal of Preventive Medicine
2023;57(8):1292-1297
- CountryChina
- Language:Chinese
-
Abstract:
The early diagnosis of lung cancer has become the focus of clinical attention, with the incidence and mortality of lung cancer increasing. Aberrant DNA methylation occurs in the primary stage of lung cancer, then the methylation degree can be changed dynamically due to the progress and the treatment of lung cancer. To date, a growing number of studies have reported that special gene methylation exploits in the clinical diagnosis, curative effect monitoring, and prognosis evaluation of lung cancer. Meanwhile, clinical trials about DNA methyltransferase inhibitors for lung cancer therapy are also underway. It is worth looking forward that detecting aberrant DNA methylation helps diagnose and treat lung cancer.
